MRD Market Insights & Trends

As advancements in molecular and genetic technologies continue to revolutionize cancer care, minimal residual disease (MRD) testing has emerged as a powerful tool for assessing treatment response, predicting disease recurrence, and guiding personalized therapeutic strategies.

For this report, we surveyed and spoke to 20 experts covering 6/10 top pharma to explore the latest trends, insights, and market sentiments shaping MRD adoption and integration into clinical practice.

Unveiling MRD: Trends in Usage and Market Sentiments

 

  • Understand how biopharma is adopting MRD today and where usage is heading next, with insights from senior precision oncology decision-makers on the expanding role of MRD in clinical development.
  • Explore investment trends, assay preferences, and unmet needs shaping the MRD market, including demand for greater sensitivity, standardization, and scalability.
  • Track the growth of MRD in lung cancer drug development, uncovering clinical trial activity, emerging opportunities, and the factors driving increased adoption across NSCLC and other indications.

 

MRD Market

You May Also Be Interested In…

Learn More About Consulting

What is Beacon Consulting?
  • We are specialist life sciences market research and consultants, delivering tailored insights across the full drug development and commercialisation lifecycle.
  • Combines scientific expertise, expert networks, and proprietary Beacon data to transform complex data into clear, strategic decisions.
  • Provides fully customised research, spanning qualitative interviews, quantitative analysis, and desk research, aligned to your specific business objectives.
  • Helps biopharma teams reduce risk, identify opportunities, and accelerate decision-making with actionable, decision-ready insights.
Learn More About Beacon Consulting

What is Beacon?

Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.

Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.

This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.

We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!

Request Demonstration

Menu
Search Icon
Close Icon
Search